A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

Launched by XINQIAO HOSPITAL OF CHONGQING · May 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how effective and safe a type of treatment called immune checkpoint inhibitors (ICIs) is when used as the first treatment for advanced cancers, such as those in the lungs, stomach, and breasts. Researchers are gathering data from patients to create a database that helps understand which factors (like certain genes or proteins) can predict how well the treatment will work. They aim to build a model that can identify which patients might benefit the most from this therapy.

To participate in the study, you need to be between 18 and 75 years old and have been diagnosed with stage IV advanced cancer. You should be able to follow the study rules and have a good chance of surviving for at least three months. Unfortunately, if you have severe heart, liver, or kidney issues, or if you have other cancers, you may not be eligible. If you join the trial, you'll be closely monitored and can contribute to important research that could help improve cancer treatments for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
• • 2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
• • 3. the stage IV according to the eighth edition of IASLC.
• • 4. PS 0-2, the expected survival \> 3 months.
• • 5. the age of 18-75 years.
• • 6. no contraindication to treatment with immune checkpoint inhibitors.
• Exclusion Criteria:
• • 1. the patients' compliance was poor, which violated the rules of the trial;
• • 2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
• • 3. the patients with other malignant tumors;
• • 4. the researchers considered that the patients should not participate in other conditions of the trial.